drugset
Drugs / ETBX-071
last change Jul 2026 re-read 2 minutes ago

ETBX-071

also known as hAd5 \[E1-, E2b-, E3-\]-PSA · hAd5 \[E1-, E2b-, E3-\]-PSA Vaccine

Vaccine

Developed for
prostate cancer · prostate carcinoma
Investigated by
ImmunityBio, Inc. · National Cancer Institute (NCI)

Trials 4 · a red edge is where a trial was stopped

today NCT07686380 · Ph 2 NCT06765902 · Ph 2 NCT06765954 · Ph 2 NCT03481816 · Ph 1
2019202020212022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03481816 Jul 2018 → Jan 2020 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 23 trials
Phase 2 NCT07686380 Jul 2026 → Jan 2029 expected prostate carcinoma National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT06765902 Dec 2025 → Jan 2031 prostate cancer ImmunityBio, Inc. Withdrawn No outcome recorded
Phase 2 NCT06765954 Dec 2025 → Jan 2031 prostate cancer ImmunityBio, Inc. Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ETBX-071 “The ETBX-071 is an adenoviral-based vaccine against PSA.” NCT07686380 ↗
3

NCT06765954 ↗

NCT06765902 ↗

NCT03481816 ↗
Known as hAd5 \[E1-, E2b-, E3-\]-PSA “ETBX-071 (hAd5 \[E1-, E2b-, E3-\]-PSA): A replication-defective human adenovirus serotype 5 (hAd5) vector modified to encode human prostate-specific antigen (PSA).” NCT06765954 ↗
Known as hAd5 \[E1-, E2b-, E3-\]-PSA Vaccine “ETBX-071 (hAd5 \[E1-, E2b-, E3-\]-PSA Vaccine): A replication-defective human adenovirus serotype 5 vector modified to encode human prostate-specific antigen (PSA).” NCT06765902 ↗
Modality Vaccine “three immunotherapeutic vaccines (ETBX-071, ETBX-061, and ETBX-051)” NCT03481816 ↗
Route Subcutaneous “The ETBX-051, ETBX-61 and ETBX-71 vaccines will be administered subcutaneously (SC)” NCT03481816 ↗